LeMaitre George W., chairman and CEO of LeMaitre Vascular (LMAT), has been a consistent seller of company stock over the past year, with Form 4 filings showing no open-market purchases during the period. Across 59 total transactions, all of the monetary value flowed in one direction: approximately $36.4 million in sales, with zero dollars spent on acquisitions. The selling has been steady and substantial, including a $16.0 million disposition on February 26, 2026, a $6.0 million sale on March 2, 2026, and combined sales of roughly $5.0 million on May 7–8, 2026. These open-market sales (code S) represent the only conviction trades, as the other filings—grants (A), option exercises (M), tax withholdings (F), and gifts (G)—are mechanical or compensatory in nature.
The pattern is unambiguous: a heavy sell bias concentrated entirely in LMAT, with no diversification into other tickers. The most recent cluster of activity, dated June 4, 2026, consists solely of zero-value grants and a gift, which do not alter the cash trajectory. The last four trades with monetary significance were all sales, reinforcing a directional trend that has persisted through the first half of 2026. While the February and March sales were the largest individual transactions, the May sales indicate the selling cadence has not abated. For shareholders tracking insider behavior, the data shows a CEO who has monetized a meaningful portion of his stake—over $36 million in roughly twelve months—without any corresponding buyback of shares on the open market.
AI-assisted summary